BioTech Medics, Inc. to Penetrate $20 Billion Energy Drink Market by Initiating Facebook & Google Ad Campaign for BioBody Bal...

   BioTech Medics, Inc.(PINKSHEETS: BMCS) announced commencing an Internet Advertising and Awareness Campaign on Facebook and Google. BioBody Balance is a caffeine-free Energy Spray nutritional supplement. BioTech's existing BioBody Balance® Concentrate Supplement has sold over $5 million in gross sales. Now consumers can enjoy the benefits of a new and improved BioBody's non-carbonated BioBody Balance Energy Spray for purchase at www.BioBodyBalance.com.

The initial BioBody Balance Facebook page is www.Facebook.com/BioBodyBalance.

"Utilizing Facebook.com and Google as marketing partners is an essential element to our advertising strategy and furthering the product branding in the market place," commented Keith Houser, CEO of Biotech Medics.

BIOBODY BALANCE® is a unique supplement with 10 years R&D. According to a California researcher investigating USA health trends, one of the top five consumer trends is for natural caffeine-free energy drinks. The U.S. energy drink industry is anticipated to reach $19.7 billion in 2013. BioBody Balance Energy Spray is a high quality pharmaceutical grade vitamin energy supplement with over 14 vitamins, minerals, amino acids with an aloe vera base for those who are concerned with boosting energy, alertness and reducing general fatigue naturally without artificial stimulants. BioBody Balance ingredients have been clinically tested to demonstrate restoring natural energy, strength, stamina and defenses.

BIOBODY BALANCE® is superior because it is sprayed sublingually 'under your tongue.' Sublingual administration has advantages over oral caffeine drinks because the product is absorbed faster. BioBody Balance is more economical as the suggested retail price is less than $.35 per serving compared to a caffeine energy drink at $2.00 or more per serving.

Safe Harbor: Forward-Looking Statements This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, in the preceding statements, the words "anticipated" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks, uncertainties and actual results could differ materially from those expressed. The FDA has not evaluated the BioBody Balance statements. BioBody Balance is not intended to diagnose, treat or cure any disease.

Contact: Tom Wood Phone: [phone]